Related Experiment Video

Updated: Jul 9, 2026

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

18.8K

Post-translational modifications in ovarian cancer: implications for immunotherapy: a mini-review

Lei Sun1, Ya-Fei Guo2, Can-Can Duan2

  • 1Department of Obstetrics & Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Journal of Ovarian Research
|October 15, 2025
PubMed

Insights

Post-translational modifications (PTMs) significantly impact ovarian cancer (OC) immunotherapy by influencing immune evasion. Understanding PTMs like ubiquitination and phosphorylation offers new strategies to improve OC treatment efficacy.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Ovarian cancer (OC) is a leading cause of gynecologic cancer mortality with poor prognosis.
  • Current immunotherapy for OC shows limited efficacy due to tumor microenvironment (TME)-driven immune evasion.

Purpose of the Study:

  • To review the role of post-translational modifications (PTMs) in modulating the immune response within the OC TME.
  • To explore how PTMs affect immune evasion and immune checkpoint molecules in ovarian cancer.

Main Methods:

  • Comprehensive literature review of PTMs in ovarian cancer immunology.
  • Focus on ubiquitination, phosphorylation, glycosylation, and acetylation.
  • Analysis of PTMs' impact on immune evasion mechanisms.

Main Results:

  • PTMs critically regulate immune responses in the OC TME.
  • Specific PTMs influence key immune checkpoint molecules and promote immune evasion.
  • Ubiquitination, phosphorylation, glycosylation, and acetylation are key PTMs involved.

Conclusions:

  • PTMs are crucial regulators of immunotherapy efficacy in ovarian cancer.
  • Targeting PTMs presents a promising avenue for overcoming OC immune evasion.
  • Further research into PTMs can lead to novel therapeutic strategies for ovarian cancer.
Keywords:
GlycosylationImmunotherapyOvarian cancerPost-translational modifications

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.7K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.